Stryker pledges to fix its Europe problem news

Stryker (NYSE:SYK) has brushed off economic troubles in the U.S. for several quarters, but it has a European crisis of its own to deal with, company officials reiterated yesterday during the medical device company’s annual analyst day in Mahwah, N.J.

Ramesh Subrahmanian, the company’s international group president, said Stryker’s troubles in Europe go beyond the weak economy there, vowing to work hard to improve the company’s performance across the pond.

"I want to clearly acknowledge that Stryker has a significant challenge and we have lagged the European market situation for sure," Subrahmanian said.

Sign up to get our free newsletters delivered right to your inbox

Stryker derived about 37% of its roughly $8 billion in sales in 2011 from international markets, from strong positions in Japan, Australia, Canada and parts of Western Europe.

But the bulk of the company’s sales come from inside the U.S., higher than its peers in the med-tech space which derive about 58% of their sales from international markets.

"Clearly, we are under-represented in international markets," Subrahmanian said.

A year into his tenure as the Kalamazoo, Mich.-based company’s international business leader, he said he’s looking to emerging markets such as China, India, Russia and Turkey as long-term growth drivers of for Stryker.

First up, however is a push to improve Stryker’s lagging performance in the European Union.

"Over the last few years, our European business has not kept pace with our own expectations," Subrahmanian said. "There are significant challenges in the EU market for sure."

It’s not the first time that Stryker has acknowledged problems with its EU operations. In a conference call with investors in July, interim CEO Curt Hartman told Leerink Swann analyst Richard Newitter that the company’s shortcomings in the EU were partly its own doing.

"We’ve had a number of ongoing organizational changes that we are working our way through, the right changes and the right structure moves to address where we see the European market moving to. And it’s been a bit of a moving target over the last couple of years for us and part of that is external environment focus," Hartman said at the time. "But we have to be intellectually honest. Part of that is our failure to execute, and we’re still a little bit playing catch-up to where the market is going and where we think we need to be.

"There’s no quick solution here. We’ve been working on this for far too long, frankly, and we just got to pay more attention to it," he said, noting that Stryker has lost market share to competitors such as Johnson & Johnson (NYSE:JNJ).

Subrahmanian said yesterday that improving market share in the EU is be a multi-stage process of re-organizing the operations and distributions channels in Southern Europe, addressing the company’s weakness in Germany and "leveraging the company’s full portfolio" while launching new products in those markets.

Long-term, he added, Stryker will look to continue its growth in emerging markets. The company derives only 6% of sales from developing nations.

"Any serious player must win in those top 5 markets," Subrahmanian said.

Although some analysts wondered if the annual meeting would be the occasion to announce a new CEO (or remoive the "interim" from Hartman’s title), there was no mention of a permanent replacement for Stephebn MacMillan, who’s abrupt ouster in February shocked med-tech.

Hartman did take care, however, to stress the experience of Stryker’s management team, which altogether boasts more than "100 years of Stryker experience."

"If you add up the broader med-tech experience of the group, it’s closer to 150 years," he told the assembled analysts. "[I]t is a seasoned med-tech team, and I think that’s very important in today’s environment, that you understand the management and leadership style that this group brings to the table each and every day."

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply